Patients with prostate cancer are increasingly confronted with different systems for rating prostate cancer treatments in Thailand but, the correlations are usually limited to publicized ratings while many of the outcomes after pancreatectomy are still unknown.

Patient volume remains a good but not generally considered a good indicator of surgical outcomes. Further investigations by Mahidol medical university did help predict some quality outcomes for patients electing to have prostate cancer surgery but not so in Immunotherapy for Prostate Cancer.

This study by Mahidol mentions several limitations that must be considered including small sample size. In addition, the limitations of the national database measures few metrics, including complication rates & mortality rates to define surgical quality. Outcomes for immunotherapy might be equally important include need for postoperative adjuvant therapy, total costs and longterm survival rates. For future research, the linkage of existing database and country access to outpatient archives will allow for better longitudinal analysis required to develop deeper understandings. Furthermore, the use of administrative data in the Kingdom of Thailand is subject to language barriers and confusion about how pre-existing conditions are measured.